{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06428500",
            "orgStudyIdInfo": {
                "id": "QTX3046-101"
            },
            "organization": {
                "fullName": "Quanta Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "QTX3046 in Patients With KRAS G12D Mutations",
            "officialTitle": "A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "in-patients-with-kras-mutations"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-07-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-16",
            "studyFirstSubmitQcDate": "2024-05-22",
            "studyFirstPostDateStruct": {
                "date": "2024-05-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Quanta Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 240,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1a: QTX3046 monotherapy dose escalation",
                    "type": "EXPERIMENTAL",
                    "description": "QTX3046 will be administered orally at escalating doses as defined in the protocol based on dose level assignment",
                    "interventionNames": [
                        "Drug: QTX3046"
                    ]
                },
                {
                    "label": "Part 1b: QTX3046 dose escalation in combination with cetuximab",
                    "type": "EXPERIMENTAL",
                    "description": "QTX3046 will be administered orally at escalating doses as defined in the protocol in combination with intravenous cetuximab based on dose level assignment",
                    "interventionNames": [
                        "Drug: QTX3046",
                        "Combination Product: Cetuximab"
                    ]
                },
                {
                    "label": "Part 2: QTX3046 monotherapy dose expansion",
                    "type": "EXPERIMENTAL",
                    "description": "QTX3046 will be administered orally at the recommended phase 2 dose (RP2D) based on cohort assignment",
                    "interventionNames": [
                        "Drug: QTX3046"
                    ]
                },
                {
                    "label": "Part 3: QTX3046 dose expansion in combination with cetuximab",
                    "type": "EXPERIMENTAL",
                    "description": "QTX3046 will be administered orally at the recommended phase 2 dose (RP2D) in combination with intravenous cetuximab based on cohort assignment",
                    "interventionNames": [
                        "Drug: QTX3046",
                        "Combination Product: Cetuximab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "QTX3046",
                    "description": "QTX3046 will be administered at protocol defined dose.",
                    "armGroupLabels": [
                        "Part 1a: QTX3046 monotherapy dose escalation",
                        "Part 1b: QTX3046 dose escalation in combination with cetuximab",
                        "Part 2: QTX3046 monotherapy dose expansion",
                        "Part 3: QTX3046 dose expansion in combination with cetuximab"
                    ]
                },
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Cetuximab",
                    "description": "Cetuximab will be administered at protocol defined dose.",
                    "armGroupLabels": [
                        "Part 1b: QTX3046 dose escalation in combination with cetuximab",
                        "Part 3: QTX3046 dose expansion in combination with cetuximab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with Treatment-emergent Adverse Events (TEAEs)",
                    "description": "Define as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab.",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Number of participants with Dose Limiting Toxicities (DLTs)",
                    "description": "DLTs will be defined as the occurrence of any of the toxicities as described in the protocol.",
                    "timeFrame": "up to 21 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Area under the plasma concentration-time curve (AUC) of QTX3046",
                    "description": "Plasma concentration data for QTX3046 will be used to evaluate the area under the plasma concentration-time curve (AUC) of QTX3046",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Peak plasma concentration of QTX3046 (Cmax)",
                    "description": "Plasma concentration data for QTX3046 will be used to evaluate peak plasma concentration (Cmax) of QTX3046",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Objective response rate (ORR)",
                    "description": "The ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) based on RECIST 1.1.",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Duration of response (DoR)",
                    "description": "Duration of response (DoR) is defined as the time between first evidence of objective response and disease progression (as measured by RECIST 1.1) or death, whichever occurs earlier, in subjects who achieve CR or PR.",
                    "timeFrame": "up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutations identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic.\n* Part 1: Advanced solid tumors with at least one prior systemic therapy.\n* Evaluable and measurable disease per RECIST v1.1.\n* Part 2 and 3: Measurable disease per RECIST v1.1\n\nExclusion Criteria:\n\n* Active brain metastasis or carcinomatous meningitis\n* Significant cardiovascular disease\n* Active infection requiring intravenous (IV) antibiotics\n* Prior treatment with a KRAS inhibitor\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Quanta Therapeutics Clinical Trials",
                    "role": "CONTACT",
                    "phone": "415-599-3892",
                    "email": "clinicaltrials@quantatx.com"
                }
            ],
            "locations": [
                {
                    "facility": "South Texas Accelerated Research Therapeutics, LLC Midwest",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Olivia Sweeney",
                            "role": "CONTACT",
                            "phone": "616-389-6674",
                            "email": "olivia.sweeney@startmidwest.com"
                        },
                        {
                            "name": "Nehal J. Lakhani, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "South Texas Accelerated Research Therapeutics, LLC San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Isabel Jimenez, RN, MSN",
                            "role": "CONTACT",
                            "phone": "210-593-5265",
                            "email": "isabel.jimenez@startsa.com"
                        },
                        {
                            "name": "Amita Patnaik, MD, FRCP(C)",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute, University of Utah",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Susan Sharry",
                            "role": "CONTACT",
                            "phone": "801-585-3453",
                            "email": "susan.sharry@hci.utah.edu"
                        },
                        {
                            "name": "Ignacio Garrido-Laguna, MD, PhD, MBA",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068818",
                    "term": "Cetuximab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M315",
                    "name": "Cetuximab",
                    "asFound": "Physician",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}